We are live on ! Find out more
CYTO icon

Altamira Therapeutics Ltd

Delisted

CYTO was delisted on the 19th of December, 2024.

8 hedge funds and large institutions have $2.54M invested in Altamira Therapeutics Ltd in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

668% more capital inflows, than outflows

Capital inflows: $4.18M | Capital outflows: $544K

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

0% more funds holding

Funds holding: 8 → 8 (0)

0.53% less ownership

Funds ownership: 26.46% → 25.93% (-0.53%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CYTO Hedge Fund Activity: Q1 2018 in Review

8 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2018, worth a combined $2.54M — down 65% from $7.2M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CYTO positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.15M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $457K sold.

  • 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $2.54M of Altamira Therapeutics Ltd stock for Q1 2018, down 65% quarter-over-quarter.
  • 4 funds opened new Altamira Therapeutics Ltd positions in Q1 2018 and 3 closed out, a net change of +1 holder.
  • The largest Altamira Therapeutics Ltd buyer in Q1 2018 was Sabby Management, an estimated $1.15M added.
  • The largest Altamira Therapeutics Ltd seller in Q1 2018 was Tekla Capital Management, an estimated $457K sold.

Based on aggregated 13F filings for Q1 2018.